IDR 400.0
(-1.48%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 599.68 Billion IDR | 139.99% |
2022 | 249.88 Billion IDR | -10.75% |
2021 | 279.99 Billion IDR | -4.42% |
2020 | 292.93 Billion IDR | 224.54% |
2019 | 90.26 Billion IDR | 29.66% |
2018 | 69.61 Billion IDR | -16.45% |
2017 | 83.32 Billion IDR | 407.44% |
2016 | 16.42 Billion IDR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 608.25 Billion IDR | 1.43% |
2024 Q2 | 733.3 Billion IDR | 20.56% |
2024 Q3 | 1011.79 Billion IDR | 37.98% |
2023 Q3 | 231.49 Billion IDR | -9.49% |
2023 Q2 | 255.75 Billion IDR | 39.13% |
2023 FY | 599.68 Billion IDR | 139.99% |
2023 Q1 | 183.82 Billion IDR | -26.44% |
2023 Q4 | 599.68 Billion IDR | 159.05% |
2022 Q2 | 390.78 Billion IDR | 37.79% |
2022 Q4 | 249.88 Billion IDR | -16.79% |
2022 Q3 | 300.3 Billion IDR | -23.15% |
2022 Q1 | 283.61 Billion IDR | 1.3% |
2022 FY | 249.88 Billion IDR | -10.75% |
2021 Q1 | 465.55 Billion IDR | 58.92% |
2021 FY | 279.99 Billion IDR | -4.42% |
2021 Q4 | 279.99 Billion IDR | -28.16% |
2021 Q3 | 389.71 Billion IDR | -44.32% |
2021 Q2 | 699.94 Billion IDR | 50.35% |
2020 FY | 292.93 Billion IDR | 224.54% |
2020 Q4 | 292.93 Billion IDR | 312.62% |
2020 Q3 | 70.99 Billion IDR | -29.86% |
2020 Q2 | 101.21 Billion IDR | 40.62% |
2020 Q1 | 71.97 Billion IDR | -20.26% |
2019 Q4 | 90.26 Billion IDR | 0.0% |
2019 Q1 | 28.7 Billion IDR | 0.0% |
2019 FY | 90.26 Billion IDR | 29.66% |
2018 FY | 69.61 Billion IDR | -16.45% |
2018 Q1 | - IDR | 0.0% |
2017 FY | 83.32 Billion IDR | 407.44% |
2016 FY | 16.42 Billion IDR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 3658.01 Billion IDR | 83.606% |
PT Kimia Farma (Persero) Tbk | 11418.56 Billion IDR | 94.748% |
PT Millennium Pharmacon International Tbk | 1361.96 Billion IDR | 55.969% |
PT Soho Global Health Tbk | 2347.86 Billion IDR | 74.458% |